27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Although patient factors remain associated with differential healthcare utilization at the end of life, utilization declined over time and use of palliative care services increased. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Prognostic discussions between caregivers of PwD and the PwD's physicians may be occurring more often; however, a high percentage of caregivers report a poor understanding about the terminal nature of dementia and the role of PC. 3 key findings →
Design: cross-sectional Participants: 80 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study supports the conclusions that diabetes increases the risk of cerebrovascular but not Alzheimer's disease pathology, and at least some of diabetes' relationship to cognitive impairment may be modified by neuropathology. 2 key findings →
Participants: 1,300 Evidence: low
Full summary, score breakdown and related studies → Original source
The accuracy of substituted judgments is associated with multiple clinically apparent patient and surrogate factors. 5 key findings →
Design: cross-sectional Participants: 250 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia management is complicated by neuropsychiatric symptoms such that the longitudinal care of a psychiatrist or other mental health provider is often an essential part of patient care and a major source of family support. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
An important goal of advance care planning (ACP) is ensuring that patients receive care concordant with their preferences. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Response rate was 54.7%. The intense pain and symptoms of individuals with dementia was alleviated less often than those of individuals with cancer (odds ratio (OR) = 0.50, P < .001), and individuals with dementia were more likely to have life-prolonging treatment withheld or withdrawn (OR = 1.40, P = .048). 5 key findings →
Participants: 8,627 Evidence: low
Full summary, score breakdown and related studies → Original source
We included 17098 records, 4139 from deceased individuals (mean age 81) and 12959 from living individuals (mean age 79). 4 key findings →
Design: case-control study Participants: 17,098 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 118,174 beneficiaries who received an AWV, 27.62% initiated ACP within 4 years compared with 17.46% of nonrecipients (HR, 1.86; 95% CI, 1.84-1.89). 5 key findings →
Design: cohort study Participants: 959,405 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 40,074 inpatient encounters (median age 72 years [IQR 62-82], 46.9% male, 22.7% Black, 4.6% Hispanic), the most common serious illness was heart failure (66.0%), followed by COPD (39.3%), kidney failure (12.4%), cancer (12.3%), and dementia (11.6%). 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
An integrated 6-mo prognostic tool was developed and validated for the HD population. 1 key finding →
Participants: 512 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Whilst nursing home managers recognise the potential benefits of advance care planning, barriers and challenges create a reluctance to facilitate. 3 key findings →
Design: cross-sectional Participants: 178 Evidence: low
Full summary, score breakdown and related studies → Original source
Approximately one-third of the Medicare beneficiaries who died in 2011 had four or more transitions within their last 6 months of life. 3 key findings →
Participants: 660,132 Evidence: low
Full summary, score breakdown and related studies → Original source
Most NH residents who use statins at the time of progression to advanced dementia continue use in follow-up. 5 key findings →
Participants: 1,699 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The purpose of this retrospective, cross-sectional study was to determine the prevalence of advance care planning (ACP) among older people presenting to an Emergency Department (ED) from the community or a residential aged care facility. 3 key findings →
Design: cross-sectional Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
A high level of drug utilization, influenced by the characteristics of residents and the institution, was observed in Belgian nursing homes. 2 key findings →
Design: cross-sectional Participants: 2,510 Evidence: low
Full summary, score breakdown and related studies → Original source
Inpatient PCC reduces 30-day readmissions and inpatient mortality with the greatest impact demonstrated within six days of hospital admission. 2 key findings →
Participants: 43,463 Evidence: low
Full summary, score breakdown and related studies → Original source
People continue to receive disease-focused therapies at the end of life rather than therapies exclusively for palliation of symptoms, suggesting that treatments may vary according to the person's primary diagnosis. 2 key findings →
Design: cross-sectional Participants: 2,623 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings are consistent with reports that care homes can provide care akin to hospice for the very old and support an approach of supporting residents to stay in their care home or own home if possible. 3 key findings →
Participants: 180 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study indicates the need to provide nurses and nursing assistants with more information about palliative care practice for people with advanced dementia. 2 key findings →
Design: cross-sectional Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source
[(18)F]flutemetamol amyloid PET detects primarily advanced stages of Aβ pathology in preclinical and symptomatic AD cases. 1 key finding →
Design: clinical trial Participants: 68 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Palliative care was associated with a higher risk of hospitalization in the first 90 days (e.g., hazard ratio (HR) 1.43 at 30 days; 95% confidence interval (CI) 1.25-1.64), which was driven predominantly by hospitalization with palliative intent, but was no longer significantly different beyond 180 days, compared to not receiving palliative care. [Correction added on 31 January 2026, after first online publication: The preceding sentence has been revised in this version.] 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants included 202 physicians and three nurse specialists who assumed similar medical responsibilities. 5 key findings →
Design: cross-sectional Participants: 202 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 209,468 decedents, 95,594 were selected after matching. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The majority of hospitalizations of NH residents with advanced dementia were due to infections and thus were potentially avoidable, because infections are often treatable in the NH. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →